Given the platinum drug shortage and the recently presented NOW trial, would you consider PARP inhibitor use in place of platinum-based chemotherapy for advanced ovarian cancer?
Community PollStarted
Given the platinum drug shortage and the recently presented NOW trial, would you consider PARP inhibitor use in place of platinum-based chemotherapy for advanced ovarian cancer?
12 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Gynecologic Oncology · Johns Hopkins Medicine - Green Spring Station
Answered on
The NOW trial results are extremely exciting and add to the growing body of data challenging the traditional upfront platinum treatment paradigms in ovarian cancer. However, without randomized data comparing PARPi to platinum/taxane-based treatment, I would not yet utilize PARPi monotherapy in the n...
Join for free or sign in to see the full answer